T he principal goals of the practice of medicine are to promote health: forestall disease, offer a cure when feasible, and ease suffering when a cure is not an option. 1 Historically, attempts to reach these goals have included unproven treatments based on traditional morés, convention, or sometimes solely reliant on the practitioner's instinct. 2 This changed dramatically with the introduction of the concept of evidencebased medicine, defined as the scrupulous and astute incorporation of the best available evidence into clinical decision making for individual patients. 3 Clinicians practicing evidence-based medicine rely on a combination of their expertise and the best available evidence 4 ; for the process to be effective, this evidence must be valid, clear, and consistent.
The first step in achieving this aim is to recognize the existence of heterogeneity inherent in individual studies and the limits that this imposes on betweenstudy comparisons and meta-analysis of data 5 ; these limits are further compounded by inexact or absent definitions of measures and outcomes, which are inherent in many reports of original research. 6 Curtailing such barriers at the origin of a study is apt to be the most successful strategy leveraged to enable harmonization of research endeavors. The creation of an easily accessible, common set of measures and outcomes for use by researchers worldwide provides an opportunity to do so. This is the intention of an effort known as the consensus measures for Phenotypes and eXposures (PhenX) project, 7 funded as a genomic resource by the National Institutes of Health (NIH) and led by RTI International. PhenX is driven by the scientific community, with overall guidance provided by the PhenX Steering Committee (SC).
Measures for the Toolkit are selected using an established consensus process. 8 Launched in 2007, the goal of PhenX is to deliver high-quality, low-burden, well-established measures to facilitate cross-study analysis of genome-wide association studies, in which even optimally designed individual investigations often lack sufficient sample sizes to address statistical power stipulations. 9 The original scope of the PhenX project included 20 research domains, with a domain defined as an area of investigation with common features and clearly itemized measures. 7 Some of the original domains included demographics, anthropometrics, complex medical conditions (eg, diabetes, cancer), body systems (eg, ocular, respiratory), and exposures (eg, nutrition and dietary supplements, physical activity, and physical fitness). 7 For each domain, a working group (WG) of 6 to 9 experts, chosen to balance domain expertise with proficiency in epidemiology, biostatistics, and genomics research, was convened and tasked with selecting (via consensus) 15 measures for inclusion in the PhenX Toolkit. 7 Available at no cost, the PhenX Toolkit (https://www.phenxtoolkit.org) is a web-based catalog that provides ready access to the standard measures of each domain along with protocols for their use. In 2013, the scope of the PhenX project was expanded to embrace rare genetic conditions and a variety of study designs as well as 4 new domains, and the April 2017 version 21.0 of the PhenX Toolkit contains 523 measures in 24 domains 10 ; one of these domains is pregnancy.
Pregnancy is a critical time during which exposures have the potential to influence the fetal phenotype significantly, as demonstrated through evolving areas of study, such as the exposome (the sum of all environmental exposures from conception through the lifespan), 11 and investigation into the developmental origins of health and disease (the hypothesis that in utero exposures at critical times induce certain changes in the fetus, some of which are at the epigenetic level, for instance, in preparation for the ex utero environment). 12 Data collected about lifestyle and biomarkers that represent environmental exposures are essential to fully understand the factors that influence maternal and fetal/neonatal health. 13 Thus, the vital need for utilization of standard measures in studies focused on the perinatal period is readily apparent, and the importance of including pregnancy as one of the PhenX Toolkit domains easily follows, supporting the endorsement of the American Congress of Obstetricians and Gynecologists of standardization of practice to improve clinical care and health outcomes. 14 Recognizing this critical need, the PhenX Pregnancy Working Group (PWG) was prioritized by the PhenX-SC. The aim of this report is to describe the consensus process and results of the PWG's deliberations and to introduce the pregnancy domain measures included in the PhenX Toolkit.
Materials and Methods
The PhenX SC, with input from the NIH PhenX liaisons, established the PWG, identifying individuals on the basis of their expertise, making a deliberate effort to include senior and junior investigators, clinician scientists, academic researchers, and at least 1 geneticist. 8 The 9 PWG members represented obstetrics, maternal-fetal medicine, pediatrics, reproductive genetics, perinatal and reproductive epidemiology, biostatistics, and toxicology. Also involved were personnel from RTI International and a representative from the PhenX-SC. The PWG roster is available on the PhenX website (https://www.phenx.org/ Default.aspx?tabid¼1066).
The PhenX SC developed the initial scope of the pregnancy domain, elements of which were refined by the PWG via a review of the PhenX Toolkit to ascertain currently existing measures, thereby allowing for cross-linkage with the new measures and avoiding duplication. Following this review, the PWG selected 15 high-priority measures reflective of the domain, recommending an established and readily available protocol for each measure according to the selection criteria previously developed by the SC (Table 1) .
Consensus on preliminary measures was reached following deliberations in the form of a 1 day, in-person meeting during which proposals for measures and protocols were presented by the PWG members for discussion as well as subsequent conference calls, e-mail Special Report ajog.org exchanges, and portal discussions. The PWG then sought input on these preliminary measures from the scientific research community, reviewed data gathered from the outreach, and selected the final measures for inclusion in the PhenX Toolkit ( Figure) .
These measures were approved by the SC for release in the PhenX Toolkit. As part of the release, data collection worksheets and dictionaries were created, the measures were linked to essential and related measures of relevance (terms described in the following text), and key words were associated with the Smart Query Tool.
An essential measure is defined as one that is critical or integral to the collection of the chosen measure; without it, data would be incomplete or interpretation of results compromised. 7 A related measure is defined as a suggested, additional PhenX measure, which may be of value to allow a researcher to use the chosen measure to its full capacity. The related measure may, for instance, permit calculation of a derived variable (eg, height and weight for the calculation of the body mass index), or it may be conceptually linked to the chosen measure (eg, annual family income and current educational attainment).
Results
The pregnancy domain is unique, yet it is closely related to specific elements already addressed by existing PhenX domains, especially the reproductive health domain. To refine the initial scope of the pregnancy domain, a review of the PhenX Toolkit identified 44 existing measures that are deemed relevant and applicable to research focusing on the perinatal period. These are listed in Table 2 To highlight the structure of the Toolkit, 3 of the included pregnancy measures are characterized in more detail, and several other measures that were considered are discussed.
Select PhenX measures

Gestational age
Gestational age is an essential component of research on pregnancy outcomes. It is often used for stratification purposes, influences interpretation of many related measures, and is inversely associated with many neonatal complications. Preterm birth closely correlates with many adverse neonatal outcomes, and its estimates are higher when best obstetric estimates of gestational age (as outlined in the following text) are used. 15 The PWG recommends that gestational age be established using criteria for determination of estimated due date adapted from the American Congress of Obstetricians and Gynecologists, 16 the American Institute of Ultrasound in Medicine, 16 the Society for Maternal-Fetal Medicine, 16 and the Society of Obstetricians and Gynaecologists of Canada. 17 With natural conception, these criteria are based on correlation of menstrual dating and ultrasound parameters, whereas with assisted reproductive technology, an assisted reproductive technologyederived estimated due date is used. If gestational age cannot be established based on medical record abstraction, a maternal interview can be used as an alternative, although this is the less preferred approach. The protocol chosen to address gestational age via maternal interview originates from the well-established Extremely Low Gestational Age Newborns Project, 18 ,19 a large-scale, multicenter, epidemiological study.
Finally, the PWG advocated consideration of the following definitions developed by a work group organized by the Eunice Kennedy Shriver National Institute of Child Health and Human Development 20 for infants born at particular gestational age time frames: early preterm (<34 weeks, 0 days), late preterm (34 weeks, 0 days to 36 weeks, 6 days), early term (37 weeks, 0 days to 38 weeks, 6 days), full term (39 weeks, 0 days to 40 weeks, 6 days), late term (41 weeks, 0 days to 41 weeks, 6 days), and postterm (42 weeks, 0 days).
Fetal growth assessment
Fetal growth is a gestational agee dependent measure of fetal size in relation to a defined standard growth curve. Fetal growth at both extremes of pathology (small and large for dates) can have a negative impact on fetal and neonatal outcomes and has been linked to various comorbidities in later life. 21, 22 ajog.org Special Report
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For the measure to be accurate, precise determination of gestational age is required. The fetal growth assessment is a 3 step process including the following: (1) ascertainment of estimated fetal weight (EFW); (2) verification of gestational age at which the EFW was recorded; and (3) determination of the weight's centile by plotting the EFW at the appropriate gestational age on a predefined fetal growth curve.
The National Standards for Fetal Growth, a Eunice Kennedy Shriver National Institute of Child Health and Human Developmentefunded multicenter project, is based on a robust methodology that accounts for racial and ethnic differences in fetal growth in US populations. The PhenX work group proposed the National Standards for Fetal Growth project as the preferred protocol. 23 The protocol is accessible and easy to use, and it does not require major equipment or specialized training.
A second protocol, the International Fetal and Newborn Consortium for the 21st Century, fetal growth standards was also considered, 24 partly because the standards were developed utilizing methods of the World Health Organization Multicenter Growth Reference Study to complete the Fetal Growth and Longitudinal Study. The PWG recommended these standards as supplemental information because debate still exists as to whether pooling of data across the 8 geographically diverse study sites was the optimal approach and also because the EFW used to calculate the fetal growth percentiles has not yet been tested outside the original study.
25,26
Prenatal and postpartum depression One in 8 new mothers suffer major postpartum depression, and a large majority experience the so-called baby blues. 27 The Edinburgh Postnatal Depression Scale was developed to screen for depression and has been validated in pregnancy. 28 The 10 question, self-reported instrument screens for depression in the previous 7 days, with a score above 9 identifying candidates who would benefit from a complete clinical assessment. 27 It is one of the most widely used, validated instruments available, has been translated into numerous languages, and has been used with diverse cultural groups, providing an excellent objective screening measure for studies on the topic. [29] [30] [31] [32] Feasibility of the use of the Edinburgh Postnatal Depression Scale as an initial universal screen for depression in the antenatal and postnatal period to identify those who may benefit from further diagnostic evaluation has also been demonstrated. 33 Other measures considered When the PhenX SC developed the original scope for this domain, very broad coverage of pregnancy-related research was proposed. In its initial deliberation, the PWG determined that some components of the scope were sufficiently covered elsewhere in the Toolkit, such as dietary intake, nutrients and supplements, and medication use. Other components failed to meet selection criteria, such as inflammatory markers associated with preterm birth (absence of a well-established protocol), biobank samples (no phenotype correlation), preeclampsia (available protocols too complicated and long for widespread use in research that may have a different overall focus), and social media (absence of an established protocol).
One further measure, which was deliberated upon for consideration for inclusion, was placental assessment. The placenta provides significant insight into environmental exposures over the course of the gestation and offers indispensable information about pregnancy outcome, as emphasized by the current NIH Human Placenta Project. [34] [35] [36] [37] While considered an asset to the domain, the placental assessment protocol lacked the prerequisite that measures in the PhenX Toolkit must be characterized by an actual phenotype and was added to the Supplemental Information section of the pregnancy domain as an additional resource for users.
Comment
The PhenX PWG was successful in adding 15 new measures uniquely suited to address outcomes pertinent to the state of pregnancy, which complement previously established measures in the PhenX Toolkit. These wellestablished, low-burden, high-quality measures offer a valuable resource to investigators and clinicians for whom pregnancy is a primary research focus but are perhaps even more indispensable for those who hold expertise in other areas and want to include pregnancy-related measures in their studies. With this in mind, the PhenX Urine samples are collected and analyzed to determine the concentrations of several phenolic compounds such as BPA used to make plastic water bottles, baby bottles, and children's toys. This bioassay also permits analysis of parabens, which are chemicals used as preservatives in foods and beverages, cosmetics, and pharmaceuticals. Some phenols and parabens are endocrine disruptors and some have been associated with adverse health effects. The NCS was planned as the largest pregnancy cohort studies in the United States, and the NHANES is a major cross-sectional study in the United States. The collection methods used in both have been validated previously.
Concentrations of trace metals
NCS biospecimen adult blood procedures: standard operating procedures NHANES, CDC laboratory procedure manual, cadmium, lead, manganese, mercury, and selenium
Blood is collected and analyzed to determine the concentrations of trace metals, which may include cadmium, lead, manganese, selenium, and mercury. High concentrations of metals in the blood may cause neurodevelopmental problems, particularly in a developing fetus or in young children. The NCS was planned as one the largest pregnancy cohort studies in the United States, and the NHANES is a major cross-sectional study in the United States. The collection methods used in both have been validated previously. ajog.org Special Report This measure is used to determine whether a woman is currently pregnant. It may be needed to determine suitability for participation in a research study and because pregnancy may influence the results of several physical and health measures such as weight and blood pressure. Depending on specific needs and implications, researchers may accept self-report of pregnancy or require a biological sample (urine or blood) for confirmation. The NHANES question on current pregnancy status was chosen for self-report. However, it was acknowledged that a biological assay is the most accurate pregnancy test and should be used for confirmation if pregnancy determination is critical to the study (ie, prior to certain investigations such as computed tomography or with the use of pharmaceutical agents). The NCS was planned as the largest pregnancy cohort studies in the United States, and the NHANES is a major cross-sectional study in the United States. The collection methods used in both have been validated previously.
Difficulties in pregnancy nuMoM2b 47 :difficulties in pregnancy visit 1, form V1E
A measure in the form of a single item (with 13 subparts) used to capture worries, concerns, and difficulties a woman has experienced related to her pregnancy. Likert-style, self-report questionnaire, administered at 6e13 weeks and again at 22e29 weeks. The nuMoM2b is a major prospective cohort study collecting data throughout pregnancy on approximately 10,000 nulliparous women. The data collection instruments were developed by the nuMoM2b investigators in collaboration with Project Scientists from the NICHD.
Family history of pregnancy complications nuMoM2b difficulties in pregnancy, maternal interview visit 2
Questions to assess a woman's family history of pregnancy complications. This is of relevance because researchers should be knowledgeable about a woman's family history of pregnancy complications, given some complications may be passed from one generation to the next. The nuMoM2b is a major prospective cohort study collecting data throughout pregnancy on approximately 10,000 nulliparous women. The data collection instruments were developed by the nuMoM2b investigators in collaboration with project scientists from NICHD.
Fetal growth assessment
Fetal growth standards based on NICHD fetal growth studies This measure includes abstraction of fetal growth and ultrasound information from a medical record. Fetal growth is a gestational ageedependent measure of fetal size, in relation to a defined standard growth curve. Fetal growth at both extremes of pathology (SGA and LGA) affects fetal and neonatal outcomes and has been linked with a variety of comorbidities encountered in later life. The fetal growth standards based on NICHD fetal growth studies offer robust methodology and account for ethnic differences in fetal growth. The protocol is accessible and easy to use. The formula chosen to calculate the EFW, which was then used to develop the fetal growth centiles, is well known and broadly used. Researchers searching for a protocol for fetal growth assessment can apply this formula with ease to calculate the EFW centile for their study, using ultrasound-derived biometry measures, which are then plotted on the available NICHD growth curves.
Gestational age (Maternal interview) ELGAN study maternal interview (medical record abstraction) GA For maternal interview, the protocol originates from the wellestablished ELGAN Project, a large-scale, multicenter, epidemiological study. Maternal record abstraction is the preferred option for establishing GA, with maternal interview provided as an alternate when medical record abstraction is untenable. GA is established using criteria for determination of EDD adapted from ACOG, AIUM, SMFM, and SOGC. Determination of EDD is based on review and correlation of menstrual dating with ultrasound parameters in natural conception and on ARTderived EDD when ART is used. Questions assessing whether medical intervention of any kind was needed to achieve pregnancy. Information about natural or assisted conception (ie, infertility treatments or reproductive technologies) is essential to determine fertility status. Questions for the maternal interview protocol have been derived from PRAMS, a major ongoing survey. Questions for the medical record abstraction protocol have been derived from the ELGAN project, a large, multicenter epidemiological study.
Mode of delivery (Maternal interview) PRAMS phase 7 standard questions (medical record abstraction) A Randomized Trial of Induction Versus Expectant Management (ARRIVE)
Information about the initiating event of a woman's delivery, the mode of delivery, and whether it was an assisted delivery. The mode of delivery may influence the health of both the mother and the neonate. Questions for the maternal interview protocol have been derived from PRAMS, a major ongoing survey.
Prenatal and postpartum depression Edinburgh Postnatal Depression Scale (EPDS)
This measure is a questionnaire that can be used to screen for recent symptoms of depression, including perinatal and postnatal depression. There are 10 questions to assess a mother's postnatal depression in the previous 7 days. A depression screening tool helps health care providers assess women for symptoms of depression before and after their pregnancy. The EPDS is one of the most widely used, validated self-report instruments to screen for depression during and after pregnancy. This measure includes abstraction of fetal growth and ultrasound information from a medical record.
ACOG, American Congress of Obstetricians and Gynecologists; AIUM, American Institute of Ultrasound in Medicine; ART, assisted reproductive technology; BPA, bisphenol A; CDC, Centers for Disease Control and Prevention; DDT, dichlorodiphenyltrichloroethane; EDD, estimated date of delivery; EFW, estimated fetal weight; ELEAT, Early Life Exposure Assessment Tool; ELGAN, Extremely Low Gestational Age Newborns; GA, gestational age; INTERGROWTH-21st, International Fetal and Newborn Consortium for the 21st Century;
LGA, large for gestational age; NCS, National Children's Study; NHANES, National Health and Nutrition Examination Survey; NICHD, Eunice Kennedy Shriver National Institute of Child Health and Human Development; nuMoM2b, Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-Be; PBDE, polybrominated diphenyl ether; PCB, polychlorinated biphenyl; PRAMS, Pregnancy Risk Assessment Monitoring System; SGA, small for gestational age; SMFM, Society for Maternal-Fetal Medicine; SOGC, Society of Obstetricians and Gynecologists of Canada.
a All measures and protocols are available at: https://www.phenxtoolkit.org/index.php?pageLink¼browse.measures&id¼240000. Beyond delivering an effortless platform for access and use of common outcome measures, the PhenX Toolkit encourages the use of standard protocols across research studies and establishes common data elements. In addition to the advantages of standard measures as they apply to genome-wide association studies, 7 these benefits also readily Advantages of standard protocols for collecting data include the ability to combine data from the following sources: (1) prevailing phenotypic and environmental exposure measures, which are historically collected in individual studies using disparate methods; (2) studies on diverse populations, allowing for validation of original findings; and (3) similar studies to increase statistical power, enabling confirmation of weak associations and exploration of rare diseases. 7 Despite the numerous benefits of the use of standard measures and protocols, the propensity for each researcher to incorporate a set of uniquely defined variables into their study remains, 40 limiting the ability to meta-analyze data across studies. The PhenX Toolkit stands well poised to champion progress in this regard, and there is evidence that PhenX measures are increasingly recognized across the scientific community. PhenX has been PhenX collaborates with the National Library of Medicine as well as the database of Genotypes and Phenotypes (https://www.ncbi.nlm.nih.gov/gap), and the data elements are posted in the NIH Common Data Elements Repository (https://cde.nlm.nih.gov/home). This approach enables ready identification of investigations using common variables, which will allow for cross-study analysis. 40 Expanding on the virtues of data harmonization, Fortier et al 9 described 2 approaches: stringent and flexible. The stringent approach calls for collection of data across studies with identical tools and protocols. Its advantages lie in ease of data synthesis, and its disadvantages include the following: (1) the challenge of imposing rigid measures and protocols across studies that are thematically, methodologically, and geographically diverse and have variable resources and funding; and (2) restriction of data synthesis solely to studies using the prescribed measures, potentially limiting generalizability and risking bias.
Conversely, the flexible approach calls for collection of data across studies with distinct tools and protocols. Its advantages include the capacity for synthesis of existing data and the ability to synthesize data across a wide breadth of studies. Its disadvantages include the challenge of safeguarding sufficient compatibility across studies to allow for valid comparisons and the challenge of synthesis across a sufficiently large number of investigations to allow for valid conclusions.
Reminiscent of the stringent approach, the PhenX Toolkit utilizes standardized protocols to ensure collected data are directly comparable, which facilitates cross-study analysis. 7 At the same time, PhenX reflects a flexible approach by providing investigators with protocols for specific measures particular to different areas of interest (eg, demographics, physical activity, and physical fitness), different patient populations (eg, age, sex), and different modes of administration (eg, interview, medical record abstraction, bioassay) to be used, as needed, in addressing specific research questions in a uniform, easily replicable manner. 42 The PhenX Toolkit also supports flexibility by providing custom data dictionaries that are compatible with REDCap and the database of Genotypes and Phenotypes. 39, 40 Another data harmonization effort, the Core Outcome Measures in Effectiveness Trials (COMET) Initiative is an example of the flexible approach. The COMET Initiative catalogs core outcome sets that were developed using prescribed methodology and pertaining to trials investigating specific clinical conditions. [43] [44] [45] [46] It has been endorsed by the Core Outcomes In Women's Health Initiative, which includes editors from more than 50 journals pertaining to women's health 43 and is encouraged by funding bodies in the United Kingdom, 44 where it originated. Core outcome sets represent a standardized set of outcomes for a particular health condition, forming the minimum expectation for trial reporting, 44 with additional outcome measures of relevance to the specific study hypothesis to be included at the investigator's discretion.
The stringent and flexible approaches are both valuable in striving for harmonization, 9 and thus, the PhenX Toolkit and the COMET Initiative should be viewed as highly complementary entities, with investigators drawing on the strengths of each to achieve the goal of standardization to strengthen global research initiatives, with the ultimate goal of improving patient care.
The key strengths of the PhenX Toolkit measures, in general, and the measures in the pregnancy domain in particular, lie in that they are well established, easily and freely accessible, and chosen with the intent of minimizing the burden on study participants and personnel. 7 The next challenge is to promote these measures' use among investigators worldwide so that the measures are adopted by a critical mass of investigators and that the aim of data synthesis across multiple studies can be realized. 9 Some of the limitations encountered by the PWG were in part imposed by the stipulations of PhenX, which in fact make the Toolkit robust. Specifically, selecting only 15 high-priority measures and also selecting only protocols meeting criteria for easy accessibility, free availability, and a low-burden nature precluded consideration of certain protocols (eg, for a multigeneration family history of reproductive issues). Similarly, certain measures had to be abandoned because no suitable protocol could be identified (eg, preeclampsia), decreasing the comprehensiveness of the pregnancy domain.
Collaborative efforts aimed at standardizing data collection methodologies will improve the quality and consistency of study data. This improvement has the potential to accelerate research progress by allowing data synthesis across studies, contributing to enhanced statistical power and the ability to draw more meaningful conclusions. The creation of the pregnancy domain with its 15 new measures is well poised to facilitate collaborative pregnancy research. To achieve this aim, investigators whose work includes the perinatal population are encouraged to utilize the PhenX Toolkit in the design and implementation of their studies. Only through concerted and well-executed research endeavors can we gain the requisite knowledge to advance pregnancy care and have a positive impact on maternal and newborn health.
